Market spiral pricing of cancer drugs
Спиральное ценообразование на противораковые препараты
2013-09-03
SCID: 54.1/ktscpyjs
Discuss with AI
cancer drug pricingdrug benefit evaluationdrug development costpatented drug prices
Figures from the paper
Abstract (AI)
High patented cancer drug prices are not related to the high cost of development or to the relative benefit of individual drugs over available ones. Several steps could be implemented to reduce these high prices to more acceptable ones.
Key Findings
1
High patented cancer drug prices are not explained by high development costs
2
High patented cancer drug prices are not related to the relative benefit of individual drugs over available alternatives
3
Implementing several unspecified policy or procedural steps could reduce cancer drug prices to more acceptable levels
Research Object
Patented cancer drugs pricing market
Research Subject
Determinants and mechanisms driving high prices (market spiral pricing) and potential steps to reduce prices to more acceptable levels
Publication Details
Publication Date
2013-09-03
Journal
Publisher
ISSN
Access Type
Author Information
Download PDF
Subscribe to digest